Member Info for technick

I have heard that testing is likely to be required for the coming 3-4 years, potentially longer in countries that won't have immediate access to vaccines. There are over 15 Bn rounds of vaccination to be delivered , going to take some time. In the mean time there is a probability that new genotypes of the virus that emerge that evade the vaccines induced immunity... what a mess...

Well done

cheers rbr08, since Dave said they were part of the tender then we have to assume we are part of the Beckman or Sysmex or both in this tender

thats for lateral flow not qPCR

not sure, someone did post both the other week and we only saw BC and Sysmex as tender suppliers so we have to assume that GDR are part of those as Dave said we were part of the tender process... it's a smart move as the relationship is with $Bn businesses and that should give confidence in delivery

should be shortly, I think too it's combined with BC for automated robotics of saliva and separately with Sysmex but please someone correct me if this is wrong

The POC Genedrive has prevented two children from going deaf, more when it gets rolled out. Wow.

I think because the market perceives this as a transient market, we need to discount that expectation, at least until we know that this is a 2,5,10 year opportunity. That said, with all of the sales combined, even at a 5x multiple that market cap seems achievable.

Agree Phil, we have to look at sales and what they support in terms of a MC, I think a more mature board discussion now over coming weeks as those approvals and sales start to drop in.

Even with the vaccines, questions will remain over what protection is provided. Certainly as long as vaccinations are required testing will also be required. There is strong evidence in other disease that when you suppress one genotype, mutations can be given a positive evolutionary pressure where they allow the virus or bacteria to evade the immune response. That needs monitoring via regular population testing.

India and US approvals seem very close but that said it looks like entry into the US market is possible before FDA approvals (see around 46 mins into the presentation).

That European sales contract is a key one very short term as it would provide income and adjust the market cap here. Although the covid market is probably a 2-3 year prospect (assuming vaccines give long term protection and don't fall over when the virus mutates), we can see combined revenues in excess of £50m+. It's starting to take shape.

Agreed, I'd assumed something in the £15m range...

Low double digit millions for the European country seems to be close to delivery.

FDA will open up BC contracts.

FDA will open up the Indian market.

a really positive and honest presentation from Dave and Matt today, enjoyable and confident things are advancing on a number of fronts and that GDR have the right partners to deliver value above the current market cap

Yeah right :-D

BB, it’s the first time a vaccine of these types will have been used, first in line anyone?! They’re talking about giving it to the elderly first, I can’t help think there’s a reason other than they’re the most vulnerable.... a man made virus to kill a natural virus, mmmm that sounds like a good idea. Why has this approach never been approved before? Because it was all still research, C19 has allowed these companies to fast track an experimental process in the guise of doing good... my opinion

I agree BB, I think there’s a lot of ulterior motives going on here, whilst approvals are missing people who knock will knock. They’ll be gone shortly. I believe in Genedrive and the GDR BOD, David will
come good very shortly...

RB, because you're buying 25% of the sample in, you loose 75% of a sample compared to a 96 well plate. You never use 384 well plates for infectious disease diagnostics because of that, you only use 384 for pharmacogenetic tests where sensitivity isn't an issue. Really is a fundamental issue and results from a brainstorm on 'how do we process more samples' - they may well not want sensitivity to be high to fudge the numbers of course...

... that's a big mistake, the sensitivity (less sample) will drop significantly. Who the fk is running these labs, they have no idea what they're doing.

Invest, agree, the fact that GDR stated there had been communication with both the FDA and WHO this month shows things are happening.... RNS's shortly on all these regs I imagine, then US and India are wide open. Steady as she goes!